Adipotide

What it is

Adipotide shrinks fat by starving it: it cuts off the small blood vessels that feed white fat so the fat tissue dies back. Monkeys lost about 11% of their body weight in a month. Their kidneys took damage doing it, and nobody has shown it works safely in a person.

The people asking about adipotide are usually not beginners. They have run a GLP-1 like semaglutide or tirzepatide, stalled, and want something that attacks fat directly rather than appetite. A few are physique competitors chasing a fast drop before a show. That is the honest audience: people who already know the standard tools and are weighing a risk most of the community will not take.

What it did in animals is real. Obese rhesus monkeys lost roughly 11% of body weight over 28 days, with imaging confirming the loss was fat and not water or muscle, and their insulin resistance improved. What it did to them matters just as much: a dose-dependent injury to the kidney tubules, called reversible under study conditions. In people there is no result to point to at all. The one human trial, run in prostate-cancer patients, was stopped early and never published a fat-loss outcome; the registry lists only the investigator's request as the reason, after four patients.

There is no established human dose, which is why the tiers here are labeled community-reported. The 250 to 500 mcg once-a-day numbers are gray-market guesses, not scaled from the monkey dosing, so you are in a strange spot: too little to know if it does anything, and still a kidney-active compound. If someone runs it anyway, the non-negotiables are baseline kidney labs (creatinine, eGFR, urine protein), a lot of water, a short run, and stopping at the first odd sign: less urine, foamy urine, swelling in the ankles. The common mistake is treating it like AOD-9604, a daily shot you forget about. It is a tissue-injury mechanism and should be run like one.

On evidence: animal 3, human 0. Everything persuasive is one primate study plus mouse work, and the single human attempt ended without an answer. That is thinner than almost anything else in the fat-loss section, and the risk is not theoretical, it was measured in the monkeys that lost the weight.

For almost everyone this is not worth it. The GLP-1 class (semaglutide, tirzepatide, retatrutide) has large human trials and loses more weight than any monkey study promised, with side effects that are annoying rather than organ-damaging. If you want a non-GLP-1 fat tool, AOD-9604 or 5-Amino-1MQ are the sane picks on this site: weaker, but nobody's kidneys are on the line.

What people use it for

Safety, in brief

The full picture — stop signs and who should talk to a doctor first — is on the dosing guide.

Sources

The labels and studies behind this page. Each link opens the original on PubMed, DailyMed or ClinicalTrials.gov.

1. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeysBarnhart et al., Sci Transl Med 2011 · Study
2. Reversal of obesity by targeted ablation of adipose tissueKolonin et al., Nat Med 2004 · Study
3. A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and ObesityClinicalTrials.gov: NCT01262664 · Trial